Company
Rivus Pharmaceuticals
Charting a New Course for Sustained CardiomMetabolic Health
- Customers
- individuals living with cardiometabolic disease
- Legal name
- Rivus Pharmaceuticals, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
At Rivus, we are focused on advancing cardiometabolic health by developing new oral medicines from our proprietary development platform.
Funding snapshot
- Total raised
- $223MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $57M2025-01-07
Funding rounds
- Round, 2025
- $57M2025-01-07, SEC form D sold, 7 investors
- Round, 2024
- $66M2024-08-09, SEC form D sold, 7 investors
- Round, 2022
- $66M2022-08-19, SEC form D sold, 7 investors
- Round, 2019
- $34.5M2019-03-26, SEC form D sold, 4 investors
Products
- Web
- HU6
- Web
- RV-8451
Loading relationship preview